Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on Opko Health (NYSE:OPK) with a price target of $12, which represents a potential upside …
Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) with a $20, following the company’s second-quarter financial results and update …
In a research report published today, Cantor analyst Youssef Squali maintained a Buy rating on Twitter (NYSE:TWTR) with a price target of $58, as …
After initiating coverage last week, MLV analyst George Zavoico is out today with his second report on Oxigene (NASDAQ:OXGN), maintaining a Buy rating with a $6.50 …
In a research report released Monday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (NASDAQ:AEZS) but reduced his price target …
In a research report sent to investors today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) with a price target …
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Peregrine Pharma (NASDAQ:PPHM) with a $5 price target, as the company presented new data from …
Maxim Group analyst Jason Kolbert maintained a Buy rating on Tekmira Pharma (NASDAQ:TKMR) with a $31 price target, which represents a potential upside …
In a research report sent to investors, MLV analyst George Zavoico initiated Buy rating on Oxigene (NASDAQ:OXGN) with a $6.50 price target, which …
Oppenheimer analyst Christopher Marai out today with his second note this week on Celldex Therapeutics (NASDAQ:CLDX) maintaining an Outperform rating, with a $36 price target, as …
